IL6 and congenital rubella syndrome: The results of this review serve to confirm that tocilizumab is the drug with the greatest efficacy in mitigating the symptoms of CRS grade 1 and 2 due to its ability to reduce the cytokines IL-2R, IL-6, IL-8, IL-10, and TNF-α without decreasing the cytotoxic capacity of CAR-T cells [37,38,39,40,41,44,46].